{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T07:13:50Z","timestamp":1773386030637,"version":"3.50.1"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Toxicol."],"abstract":"<jats:p>\n                    Drug-induced liver injury (DILI) remains a leading cause of clinical trial attrition and post-marketing drug withdrawals. Its prediction is hindered by the limited physiological relevance and interindividual variability captured in conventional preclinical models. To overcome this, we developed a human serum-derived educated spheroid system incorporating human blood sera from donors to generate liver spheroids that recapitulate human hepatic diversity. This platform enables clinical trial-in-a-dish studies and supports acute and chronic treatment regimens. Using a panel of drugs spanning the full DILI risk spectrum, we evaluated hepatotoxic potential through a proprietary AI-driven algorithm that integrates severity and incidence metrics at therapeutic concentrations. Our platform reliably distinguished low-risk from high-risk DILI compounds and recapitulated both dose-dependent and idiosyncratic toxicity profiles. Notably, ximelagatran-induced DILI was only detected under chronic exposure conditions, mirroring clinical outcomes. Transcriptomic profiling revealed innate immune activation in DILI-positive individuals. STRING analysis further implicated HLA-DRB1 and HLA-DQA1 interactions via\n                    <jats:italic>VIM<\/jats:italic>\n                    upregulation in macrophages and dendritic cells, suggesting a mechanistic link to immune-mediated iDILI. In exploratory prospective studies, our system predicted ribociclib-induced grade 3 DILI in one ER+\/HER2\u2212 breast cancer patient and absence of DILI in two patients, consistent with clinical outcomes. These findings highlight the value of integrating our model with our AI-based mapping strategy to enable mechanistic classification of DILI, deconvolution of immune-related toxicity, and prediction of patient-specific risk. Our platform represents a step toward personalized hepatotoxicity assessment and improved translational toxicology strategies.\n                  <\/jats:p>","DOI":"10.3389\/ftox.2026.1740791","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T02:26:36Z","timestamp":1773368796000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["AI-enhanced clinical trial-in-a-dish platform for improved DILI risk classification and mechanistic insights into hepatotoxicity"],"prefix":"10.3389","volume":"8","author":[{"given":"Sara","family":"Cherradi","sequence":"first","affiliation":[{"name":"PredictCan Biotechnologies SAS, Biop\u00f4le Eurom\u00e9decine","place":["Grabels, France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salom\u00e9","family":"Roux","sequence":"additional","affiliation":[{"name":"PredictCan Biotechnologies SAS, Biop\u00f4le Eurom\u00e9decine","place":["Grabels, France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Bailleux","sequence":"additional","affiliation":[{"name":"Department of Oncology, Centre Antoine LACASSAGNE","place":["Nice, France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cl\u00e9ment","family":"Devic","sequence":"additional","affiliation":[{"name":"D\u00e9partement d'\u00c9pid\u00e9miologie, de Biostatistique et des Donn\u00e9es de Sant\u00e9 (DEBDS), Centre Antoine LACASSAGNE","place":["Nice, France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colin","family":"Debaigt","sequence":"additional","affiliation":[{"name":"D\u00e9l\u00e9gation \u00e0 la Recherche Clinique et \u00e0 l\u2019Innovation (DRCI), Centre Antoine LACASSAGNE","place":["Nice, France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamelia","family":"Guerda","sequence":"additional","affiliation":[{"name":"D\u00e9l\u00e9gation \u00e0 la Recherche Clinique et \u00e0 l\u2019Innovation (DRCI), Centre Antoine LACASSAGNE","place":["Nice, France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samantha","family":"Luciano","sequence":"additional","affiliation":[{"name":"Centre de Ressources Biologiques, Centre Antoine LACASSAGNE","place":["Nice, France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00e9lanie","family":"Dalle","sequence":"additional","affiliation":[{"name":"PredictCan Biotechnologies SAS, Biop\u00f4le Eurom\u00e9decine","place":["Grabels, France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong Tuan","family":"Duong","sequence":"additional","affiliation":[{"name":"PredictCan Biotechnologies SAS, Biop\u00f4le Eurom\u00e9decine","place":["Grabels, France"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1002\/jgf2.600","article-title":"Sample size determination: a practical guide for health researchers","volume":"24","author":"Althubaiti","year":"2023","journal-title":"J. Gen. Fam. Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"rky014","DOI":"10.1093\/rap\/rky014","article-title":"Altered cytokine expression by macrophages from HLA-B27-positive spondyloarthritis patients without evidence of endoplasmic reticulum stress","volume":"2","author":"Ambarus","year":"2018","journal-title":"Rheumatol. Adv. Pract."},{"key":"B3","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s12915-024-01975-1","article-title":"Non-human peptides revealed in blood reflect the composition of intestinal microbiota","volume":"22","author":"Arapidi","year":"2024","journal-title":"BMC Biol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e71817","DOI":"10.7759\/cureus.71817","article-title":"Ribociclib-induced autoimmune hepatitis: a case report","volume":"16","author":"Atay","year":"2024","journal-title":"Cureus"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1007\/s00204-020-02682-w","article-title":"Functionality of primary hepatic non-parenchymal cells in a 3D spheroid model and contribution to acetaminophen hepatotoxicity","volume":"94","author":"Bell","year":"2020","journal-title":"Arch. Toxicol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ejim.2021.10.035","article-title":"Drug-induced liver injury: pathogenesis, epidemiology, clinical features, and practical management","volume":"97","author":"Bjornsson","year":"2022","journal-title":"Eur. J. Intern. Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.drudis.2011.05.007","article-title":"FDA-Approved drug labeling for the study of drug-induced liver injury","volume":"16","author":"Chen","year":"2011","journal-title":"Drug Discov. Today"},{"key":"B8","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/s41422-018-0111-x","article-title":"Conversion of hepatoma cells to hepatocyte-like cells by defined hepatocyte nuclear factors","volume":"29","author":"Cheng","year":"2019","journal-title":"Cell Res."},{"key":"B9","doi-asserted-by":"crossref","DOI":"10.1007\/s44164-023-00057-w","article-title":"An original donor-dependent spheroid system for the prediction of idiosyncratic drug-induced liver injury risk","volume-title":"In vitro","author":"Cherradi","year":"2023"},{"key":"B10","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1080\/15476278.2021.1992216","article-title":"Human hepatocytes isolated from explanted livers: a powerful tool to understand end-stage liver disease and drug screening","volume":"17","author":"Faccioli","year":"2021","journal-title":"Organogenesis"},{"key":"B11","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1067\/mcp.2001.114667","article-title":"The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions","volume":"69","author":"Fattinger","year":"2001","journal-title":"Clin. Pharmacol. Ther."},{"key":"B12","doi-asserted-by":"publisher","first-page":"17562848231163410","DOI":"10.1177\/17562848231163410","article-title":"Drug-induced liver injury: a comprehensive review","volume":"16","author":"Hosack","year":"2023","journal-title":"Ther. Adv. Gastroenterol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1146\/annurev-pathmechdis-051122-094016","article-title":"Acetaminophen hepatotoxicity: Paradigm for understanding mechanisms of drug-induced liver injury","volume":"19","author":"Jaeschke","year":"2024","journal-title":"Annu. Rev. Pathol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/978-3-642-00663-0_13","article-title":"Drug-induced liver injury in humans: the case of ximelagatran","author":"Keisu","year":"2010","journal-title":"Handb. Exp. Pharmacol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"434010","DOI":"10.1155\/2013\/434010","article-title":"Cytokine levels in the serum of healthy subjects","volume":"2013","author":"Kleiner","year":"2013","journal-title":"Mediat. Inflamm."},{"key":"B16","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1183\/09031936.00091610","article-title":"Sitaxentan-related acute liver failure in a patient with pulmonary arterial hypertension","volume":"37","author":"Lee","year":"2011","journal-title":"Eur. Respir. J."},{"key":"B17","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1590\/abd1806-4841.20143705","article-title":"Sample size: how many participants do I need in my research?","volume":"89","author":"Martinez-Mesa","year":"2014","journal-title":"An Bras Dermatol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"100147","DOI":"10.1016\/j.dmd.2025.100147","article-title":"Animal product-free formation and cultivation of three-dimensional primary hepatocyte spheroids","volume":"53","author":"Mickols","year":"2025","journal-title":"Drug Metab. Dispos."},{"key":"B19","doi-asserted-by":"publisher","first-page":"102549","DOI":"10.1016\/j.is.2025.102549","article-title":"The effects of data quality on machine learning performance on tabular data","volume":"132","author":"Mohammed","year":"2025","journal-title":"Inf. Syst."},{"key":"B20","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s13058-023-01701-9","article-title":"Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+\/HER2-advanced breast cancer receiving first-line ribociclib plus fulvestrant","volume":"25","author":"Neven","year":"2023","journal-title":"Breast Cancer Res."},{"key":"B21","doi-asserted-by":"publisher","first-page":"11397","DOI":"10.1021\/acs.jmedchem.0c00524","article-title":"Drug induced liver injury (DILI). Mechanisms and medicinal chemistry avoidance\/mitigation strategies","volume":"63","author":"Norman","year":"2020","journal-title":"J. Med. Chem."},{"key":"B22","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.yrtph.2012.05.017","article-title":"An overview of the preclinical toxicity and potential carcinogenicity of sitaxentan (thelin(R)), a potent endothelin receptor antagonist developed for pulmonary arterial hypertension","volume":"64","author":"Owen","year":"2012","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.bbalip.2015.10.008","article-title":"Culturing of HepG2 cells with human serum improve their functionality and suitability in studies of lipid metabolism","volume":"1861","author":"Pramfalk","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"key":"B24","doi-asserted-by":"publisher","first-page":"7354","DOI":"10.3390\/ijms25137354","article-title":"Macrophages and HLA-class II alleles in multiple sclerosis: insights in therapeutic dynamics","volume":"25","author":"Prapas","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"B25","doi-asserted-by":"publisher","first-page":"115938","DOI":"10.1016\/j.biopha.2023.115938","article-title":"C\/EBPbeta: the structure, regulation, and its roles in inflammation-related diseases","volume":"169","author":"Ren","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"B26","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1124\/jpet.109.162651","article-title":"Intrinsic versus idiosyncratic drug-induced hepatotoxicity--two villains or one?","volume":"332","author":"Roth","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1378371","DOI":"10.3389\/fphar.2024.1378371","article-title":"Exploiting the predictive power of educated spheroids to detect immune-mediated idiosyncratic drug-induced liver injury: the case of troglitazone","volume":"15","author":"Roux","year":"","journal-title":"Front. Pharmacol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"3875","DOI":"10.1007\/s00204-024-03833-z","article-title":"Uncovering the mechanism of troglitazone-mediated idiosyncratic drug-induced liver injury with individual-centric models","volume":"98","author":"Roux","year":"","journal-title":"Arch. Toxicol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1256783","DOI":"10.3389\/fonc.2023.1256783","article-title":"Ribociclib-induced liver injury: a case report","volume":"13","author":"Schaeffer","year":"2023","journal-title":"Front. Oncol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1038\/nm.4185","article-title":"Signals from the gut microbiota to distant organs in physiology and disease","volume":"22","author":"Schroeder","year":"2016","journal-title":"Nat. Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1158\/1078-0432.CCR-17-2369","article-title":"FDA approval: ribociclib for the treatment of postmenopausal women with hormone receptor-positive, HER2-Negative advanced or metastatic breast cancer","volume":"24","author":"Shah","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"B32","doi-asserted-by":"publisher","first-page":"11685","DOI":"10.1038\/s41598-018-29763-2","article-title":"Establishing normal metabolism and differentiation in hepatocellular carcinoma cells by culturing in adult human serum","volume":"8","author":"Steenbergen","year":"2018","journal-title":"Sci. Rep."},{"key":"B33","doi-asserted-by":"publisher","first-page":"891281","DOI":"10.3389\/fcell.2022.891281","article-title":"Extracellular vimentin is expressed at the rear of activated macrophage-like cells: potential role in enhancement of migration and phagocytosis","volume":"10","author":"Thalla","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"837","DOI":"10.3389\/fphar.2019.00837","article-title":"Mechanistic studies of idiosyncratic DILI: clinical implications","volume":"10","author":"Uetrecht","year":"2019","journal-title":"Front. Pharmacol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1038\/s41598-021-82195-3","article-title":"HLA-DRB1 allelic epitopes that associate with autoimmune disease risk or protection activate reciprocal macrophage polarization","volume":"11","author":"Van Drongelen","year":"2021","journal-title":"Sci. Rep."},{"key":"B36","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1007\/s00204-020-02763-w","article-title":"The evolution of strategies to minimise the risk of human drug-induced liver injury (DILI) in drug discovery and development","volume":"94","author":"Walker","year":"2020","journal-title":"Arch. Toxicol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"e2209936120","DOI":"10.1073\/pnas.2209936120","article-title":"Microbiota-induced active translocation of peptidoglycan across the intestinal barrier dictates its within-host dissemination","volume":"120","author":"Wheeler","year":"2023","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B38","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1146\/annurev-pharmtox-030220-015007","article-title":"Models of idiosyncratic drug-induced liver injury","volume":"61","author":"Yokoi","year":"2021","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.molimm.2018.09.017","article-title":"Extracellular vimentin modulates human dendritic cell activation","volume":"104","author":"Yu","year":"2018","journal-title":"Mol. Immunol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1182\/blood-2011-01-331157","article-title":"SHP2 tyrosine phosphatase stimulates CEBPA gene expression to mediate cytokine-dependent granulopoiesis","volume":"118","author":"Zhang","year":"2011","journal-title":"Blood"}],"container-title":["Frontiers in Toxicology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/ftox.2026.1740791\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T02:26:38Z","timestamp":1773368798000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/ftox.2026.1740791\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,13]]},"references-count":40,"alternative-id":["10.3389\/ftox.2026.1740791"],"URL":"https:\/\/doi.org\/10.3389\/ftox.2026.1740791","relation":{},"ISSN":["2673-3080"],"issn-type":[{"value":"2673-3080","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,13]]},"article-number":"1740791"}}